Fulvestrant Injection
Product Images NDC 0143-9022

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 0143-9022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Fulvestrant Injection 1)

FDA Label Image

Figure9 (Fulvestrant Injection 10)

This is a chart showing the progression-free survival probability (%) over time (in months) for patients using different treatments (fulvestrant with either palbociclib or placebo). The numbers on the left show the percentage of survival probability and the numbers on the bottom show the time in months. The chart also shows the number of patients at risk for each treatment.*

FDA Label Image

Figure10 (Fulvestrant Injection 11)

This is a graph showing the comparison of Fulvestrant with and without Palbociclib and placebo. The graph compares the number of patients at risk over time (in months). The number of patients receiving Fulvestrant plus Palbociclib is noted as FULWPAL, Fulvestrant plus placebo is FULWPCB, and PCB represents the placebo group.*

FDA Label Image

Figure11 (Fulvestrant Injection 12)

This appears to be a graph showing the Free Survival Probability of patients (represented by percentages) over a period of time (in months) for three different treatments. Two of the treatments are labeled as "Fulvestrant plus Placebo" and the third treatment is labeled as "Fulvestrant plus Abemacicib". There are censored observations on the graph as well.*

FDA Label Image

Figure12 (Fulvestrant Injection 13)

The text seems to be a table showing the results of a study that compares the effects of two different treatments (Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo) over time (in months). Unfortunately, the process generated some errors, as there are some numbers and characters that do not seem to make sense or belong to the context. The text is not very readable, and it may be best to look for the original source of the data.*

FDA Label Image

Figure13 (Fulvestrant Injection 14)

FDA Label Image

Figure14 (Fulvestrant Injection 15)

FDA Label Image

Hikma Syringe (Fulvestrant Injection 16)

This is a description of Fulvestrant Injection which is a prescription medicine administered through intramuscular injection. The medicine comes in a single-dose pre-filled syringe of 250mg per 5mL (50mg per 1 mL). The NDC code for this medicine is 0143-9022-01. It should be noted that it is only meant for use as directed by a healthcare professional, and should be protected from light during storage. The rest of the text contains errors from and is not-useful.*

FDA Label Image

Fulvestrant Carton (Fulvestrant Injection 17)

FDA Label Image

Figure2 (Fulvestrant Injection 2)

FDA Label Image

Figure3 (Fulvestrant Injection 3)

FDA Label Image

Figure4 (Fulvestrant Injection 4)

FDA Label Image

Figure5 (Fulvestrant Injection 5)

FDA Label Image

Structure (Fulvestrant Injection 6)

FDA Label Image

Figure6 (Fulvestrant Injection 7)

This is a table showing the progression-free survival of patients in two treatment groups - Fulvestrant 250mg and Fulvestrant 500mg. The table presents the proportion of patients who experienced a progression-free survival, along with the number of patients at risk in each group.*

FDA Label Image

Figure7 (Fulvestrant Injection 8)

FDA Label Image

Figure8 (Fulvestrant Injection 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.